Source: http://www.google.es/patents/US8133506?dq=flatulence
Timestamp: 2013-05-21 14:19:36
Document Index: 245888671

Matched Legal Cases: ['Application No. 570039', 'Application No. 569984', 'Application No. 2008134900', 'Application No. 2008134912', 'Application No. 200780011406', 'Application No. 200780011485', 'Application No. 598']

Patente US8133506 - Drug delivery systems comprising weakly basic drugs and organic acids - Google PatentesB�squeda Im�genes Maps Play YouTube Noticias Gmail Drive M�s » B�squeda avanzada de patentes | Historial web | Iniciar sesi�n B�squeda avanzada de patentesPatentesThe present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble...http://www.google.es/patents/US8133506?utm_source=gb-gplus-sharePatente US8133506 - Drug delivery systems comprising weakly basic drugs and organic acids N�mero de publicaci�nUS8133506 B2Tipo de publicaci�nConcesi�n N�mero de solicitud12/209,285 Fecha de publicaci�n13 Mar 2012 Fecha de presentaci�n12 Sep 2008 Fecha de prioridad12 Mar 2008Tambi�n publicado comoCN101977593AEP2265261A1US20090232885WO2009114606A1 InventoresJin-Wang LaiVivek PurohitGopi VenkateshNehal H. Vyas Cesionario originalAptalis Pharmatech, Inc.Bank Of America, N.A., As Administrative AgentEurand, Inc. Clasificaci�n de EE.UU.424/455514/397424/497 Clasificaci�n internacionalA61K9/48A61K31/4178A61K9/16 Clasificaci�n cooperativaA61K31/4178A61K9/1623A61K9/1617A61K9/1652A61K9/5078A61K9/1635 Clasificaci�n europeaA61K9/50K2A61K31/4178A61K9/16H6BA61K9/16H6FA61K9/16H4A61K9/16H4BReferenciasCitas de patentes (45)Otras citas (25)Enlaces externosUSPTO Cesi�n de USPTO EspacenetDrug delivery systems comprising weakly basic drugs and organic acidsUS 8133506 B2 Resumen The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble drug and a pharmaceutically acceptable organic acid separated from each other by an SR layer; the RR particles each comprise the weakly basic, poorly soluble drug, and release at least about 80 wt. % of the weakly basic, poorly soluble drug in about 5 minutes when dissolution tested using United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2�paddles@50 RPM and a two-stage dissolution medium at 37� C. (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8).
1. A pharmaceutical composition comprising a plurality of timed pulsatile release and rapid release particles, wherein:
Citas de patentes Patente citada Fecha de presentaci�n Fecha de publicaci�n Solicitante T�tuloUS363458413 Feb 196911 Ene 1972American Home Products Corp.Sustained action dosage formUS391781320 Mar 19744 Nov 1975A/S Alfred BenzonOral drug preparationsUS395495927 Ago 19754 May 1976A/S Alfred BenzonOral drug preparationsUS40839498 Jul 197411 Abr 1978Byk Gulden Lomberg Chemische Fabrik GmbhNew oral form of medicament and a method for producing itUS436154615 Jun 198130 Nov 1982Boehringer Ingelheim GmbhRetard form of pharmaceuticals with insoluble porous diffusion coatingsUS436721731 Dic 19804 Ene 1983Boehringer Ingelheim GmbhDipyricamole sustained release forms comprising lacquer-coated particles and the preparation thereofUS442764817 Jun 198224 Ene 1984Dr. Karl Thomae GmbhDipyridamole-containing pharmaceutical formUS443809130 Jun 198220 Mar 1984Dr. Karl Thomae GmbhBromhexine delayed-release pharmaceutical formUS445927918 Ago 198210 Jul 1984Boehringer Ingelheim GmbhRetard form of pharmaceuticals with insoluble porous diffusion coatingsUS457826427 Abr 198425 Mar 1986Boehringer Ingelheim GmbhRetard form of pharmaceuticals with insoluble porous diffusion coatingsUS45967057 Oct 198324 Jun 1986Dr. Karl Thomae GmbhOral mopidamol preparationUS466315021 May 19865 May 1987Elan Corporation P.L.C.Sustained absorption pharmaceutical compositionUS471604020 Dic 198429 Dic 1987Elan Corporation P.L.C.Controlled absorption methyldopa pharmaceutical formulationUS472161920 Dic 198426 Ene 1988Elan Corporation P.L.C.Controlled absorption diltiazen pharmaceutical formulationUS47269511 Jul 198523 Feb 1988Elan Corporation P.L.C.New pharmaceutical forms for administration of medicaments by oral route, with programmed releaseUS482052116 Ene 198711 Abr 1989Eland Corporation P.L.C.Sustained absorption pharmaceutical compositionUS482668812 Nov 19862 May 1989501 Elan Corporation PLC.Controlled absorption pharmaceutical formulationUS486374219 Jun 19875 Sep 1989Elan Corporation PlcControlled absorption pharmaceutical compositionUS489424016 Nov 198716 Ene 1990Elan Corporation PlcControlled absorption diltiazem formulation for once-daily administrationUS532085322 Dic 199214 Jun 1994Merrell Dow Pharmaceuticals Inc.Controlled release formulation for pharmaceutical compoundsUS570519019 Dic 19956 Ene 1998Abbott LaboratoriesControlled release formulation for poorly soluble basic drugsUS584032915 May 199724 Nov 1998Bioadvances LlcPulsatile drug delivery systemUS601557712 Abr 199518 Ene 2000Dr. Karl Thomae GmbHPharmaceutical compositions containing dipyridamole or mopidamol and acetylsalicylic acid or the physiologically acceptable salts thereof, processes for preparing them and their use in treating clot formationUS65963114 Mar 199922 Jul 2003Eurand International S.P.A.Fast disintegrating tabletsUS660252129 Sep 19985 Ago 2003Impax Pharmaceuticals, Inc.Multiplex drug delivery system suitable for oral administrationUS664552414 Ago 200111 Nov 2003Pierce Management LlcOral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agentUS670280322 Ene 20019 Mar 2004Delsys Pharmaceutical CorporationMulti-step drug dosage formsUS200100469647 Feb 200129 Nov 2001Percel PhillipTimed pulsatile drug delivery systemsUS2003011337425 Ene 200219 Jun 2003Aptalis Pharmatech, Inc.Pulsatile release histamine H2 antagonist dosage formUS2003017030430 Ene 200311 Sep 2003Alkermes, Inc.Multiparticulate modified release compositionUS2004001909623 Oct 200129 Ene 2004Smithkline Beecham CorporationNovel formulations of carvedilolUS200402587498 Oct 200223 Dic 2004Gramatte ThomasOral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredientUS2005023298819 Abr 200420 Oct 2005Eurand Pharmaceuticals Ltd.Orally disintegrating tablets and methods of manufactureUS2005023871722 Jun 200527 Oct 2005Duerig ThomasAmino acid modulated extended release dosage formUS2005028721128 Abr 200529 Dic 2005Astellas Pharma Inc.Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this compositionUS200602807958 Jun 200514 Dic 2006Dexcel Pharma Technologies, Ltd.Specific time-delayed burst profile delivery systemUS2007019014529 Ene 200716 Ago 2007Eurand, Inc.Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acidsUS2007019649129 Ene 200723 Ago 2007Eurand, Inc.Drug delivery systems comprising weakly basic drugs and organic acidsEP0032562A117 Dic 198029 Jul 1981Dr. Karl Thomae GmbHDipyridamol retard-forms and process for their preparationEP1123700A19 Feb 200116 Ago 2001Eurand America, IncorporatedTimed pulsatile drug delivery systemsWO2002036558A230 Oct 200110 May 2002Aronhime, JudithNovel crystal and solvate forms of ondansetron hydrochloride and processes for their preparationWO2003104192A26 Jun 200318 Dic 2003Torrent Pharmaceuticals LimitedControlled release formulation of lamotrigineWO2004096182A127 Abr 200411 Nov 2004Anand, OmExtended release matrix tablets of carvedilolWO2005065640A15 Ene 200521 Jul 2005Jain, RajeshCompositions of buccal dosage forms for extended drug release and the process of preparing such compositionsWO2005077341A117 Ene 200525 Ago 2005Mathur, Rajeev, ShankerOrally disintegrating pharmaceutical compositions of ondansetronOtras citasReferencia1Communication and annex from the European Patent Office Examining Division, issued Feb. 25, 2009 (EP07717476.1).2Communication and annex from the European Patent Office Examining Division, issued Mar. 6, 2009 (EP07717465.4).3Communication from the European Patent Office enclosing Third Party Observations in European application serial No. EP07717476.1, mailed Mar. 18, 2010.4Communication from the Intellectual Property Office of New Zealand corresponding to New Zealand Patent Application No. 570039, mailed on Mar. 16, 2010.5Communication from the Intellectual Property Office of New Zealand for New Zealand Patent Application No. 569984, mailed on Mar. 16, 2010.6International Preliminary Report on Patentability for PCT/US2007/061217, mailed Oct. 28, 2009.7International Preliminary Report on Patentability for PCT/US2007/061237, mailed Nov. 3, 2009.8International Preliminary Report on Patentability: PCT/US2009/036787 (Sep. 14, 2010).9International Search Report for International Application No. PCT/US2007/061217, mailed Sep. 26, 2007.10International Search Report for International Application No. PCT/US2007/061237, mailed Sep. 7, 2007.11Invitation to Respond to Written Opinion and Second Written Opinion issued Jan. 6, 2010, Singapore Patent Office.12Invitation to Respond to Written Opinion and Written Opinion issued Sep. 7, 2009, Singapore Patent Office.13Offical Action from the Russia Patent Office for Russian Patent Application No. 2008134900 (Sep. 29, 2010) (translation).14Offical Action from the Russia Patent Office for Russian Patent Application No. 2008134912 (Sep. 22, 2010) (translation).15Office Action from the Chinese Patent Office for Chinese Patent Application No. 200780011406.8 (Sep. 13, 2010) (translation).16Office Action from the Chinese Patent Office for Chinese Patent Application No. 200780011485.2 (Jun. 12, 2010) (translation).17Opposition Document filed in the Chilean Patent Department for Chilean Patent Application No. 598/2009 (translation).18Remington, The Science and Practice of Pharmacy, 2Ist Ed., Chpt 46 pages 932-933 (2005).19Sigma-Aldrich, Ondansetron hydrochloride dihydrate, O3639, p. 1, 2010.20Venkatesh, Gopi, "Development of Controlled-Release SK&F 82526-J Buffer Bead Formulations with Tartaric Acid as the Buffer," Pharmacutical Development and Technology, 3(4), 477-485 (1998).21West, Anthony R., Solid State Chemistry and its Applications, Wiley, New York, 1988, pp. 358 & 365.22Written Opinion of the International Searching Authority for PCT/US2007/061217, mailed Sep. 26, 2007.23Written Opinion of the International Searching Authority for PCT/US2007/061237, mailed Sep. 7, 2007.24Written Opinion of the International Searching Authority for PCT/US2009/036787, mailed May 14, 2009.25Young, Lee W., "International Search Report," 2 pages, from International Application No. PCT/US09/36787, filed Mar. 11, 2009, United States Patent and Trademark Office, Alexandria, Virginia, United States of America (mailed May 14, 2009).GirarImagen originalP�gina principal de Google - Sitemap - Descargas masivas de USPTO - Pol�tica de privacidad - Condiciones de servicio - Acerca de Google Patentes - Danos tu opini�nDatos proporcionados por IFI CLAIMS Patent Services©2012 Google